In April 2024, Johnson & Johnson announces that the company will showcase the comprehensive range of clinical and real world evidences for the purpose of its cardiovascular portfolio at the American College of Cardiology in its 73 annual scientific session. The company will feature 11 abstracts that includes five oral presentation. These oral presentation highlights the therapeutics benefits of its cardiovascular products and technologies.
The presentation will also focus on the company innovative solutions for treating the cardiovascular diseases. These diseases include its Absorb bioresorbable scaffold and the Biosense Webster. The data presented will demonstrate the safety and efficacy of these technology in improving patient outcomes.
One of the key highlight of the presentation is the new data on the company’s X-ray based technology, which has shown promising results for the treatment of cardiovascular diseases. The company experts will also discuss the new advancement in its abdominal aortic aneurysm repair technology. It has the potential to revolutionize the treatment of this conditions.
As per the report published by Coherent Market Insights, the global Myocardial Infarction market is poised to hold a CAGR of 5.9% from 2021 to 2028. In, 2028, the revenue will reach to US$ 2,714.8 million from US$ 1,816.8 Million in 2021. Increasing prevalence of heart attack is expected to drive demand in the global Myocardial Infarction Market during the forecast period.
Another factor that will lead to drive growth is the increasing rate of clinical trial for the treatment of castrate-resistant prostate cancer. Additionally, the introduction of innovative therapies along the diagnostic technologies will aid in driving demand. Novel anticoagulants and antiplatelet drugs are improving post-infraction management by reducing the subsequent events.
Moreover, advancement in the stent technologies is predominantly impacting the treatment and the management of Myocardial Infarction. This provide better outcomes to the patient dealing with coronary artery diseases.
Additionally, the development of innovative drug eluting stents will also aid in fueling demand. These stents will aid in releasing medicines that will help in preventing re-narrowing of arteries, this will aid in addressing the major restrain in the traditional stent models.
Rising usage of hybrid stents that combines the benefits of both the bioresorbable material and drug-elution material are being explored. These stent provides support and drug delivery to gradual resorption. It helps in restoring natural vessels functions with time.
Advancement made in the field of pharmacological therapies will aid in improving the Myocardial Infarction Market outcomes. This offers new hope for the patients with enhanced efficacy and safety profiles. Introduction of next generation antiplatelet agents plays a crucial role in the prevention of thrombotic event in post Myocardial Infarction.
However, the integration of digital health tools in the Myocardial Infarction Market is set to revolutionize the patient care, and enhance monitoring. The major example of this is use in wearable devices that will monitor vital signs including rhythm and heart rate.
